VBI Vaccines Inc. (TSE:VBV – Get Free Report)’s share price fell 5.1% on Monday . The stock traded as low as C$4.82 and last traded at C$4.82. 1,300 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 3,637 shares. The stock had previously closed at C$5.08.
VBI Vaccines Stock Performance
The stock has a market cap of C$308.86 million and a PE ratio of -4.97. The company has a current ratio of 2.64, a quick ratio of 2.54 and a debt-to-equity ratio of 14.29.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
Further Reading
- Five stocks we like better than VBI Vaccines
- NYSE Stocks Give Investors a Variety of Quality Options
- Rocket Lab is the Right Stock for the Right Time
- What Are the U.K. Market Holidays? How to Invest and Trade
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Investing in Commodities: What Are They? How to Invest in Them
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
